This grant application requests five years of renewed support for the Arizona Alzheimer's Disease Core Center (ADCC). The ADCC is intended to optimize the development and use of its Cores, advance the scientific understanding, unusually early detection, and tracking of AD, and the accelerated evaluation of AD modifying and prevention therapies, promote additional organizational investments, and provide a model of statewide collaboration in AD research. The Administrative Core provides the leadership and support needed to optimize the development, interactions, and use of its Cores. It works closely with researchers inside and outside Arizona, the National Alzheimer's Coordinating Center (NACC), and other AD Centers to promote the development and progress of AD-related studies and collaborations. It administers a program for the statewide solicitation, competitive review, and support of pilot studies. It helps solve the challenges and fulfill the opportunities associated with the ADCC's statewide collaborative model and ensures the ADCC's accountability to the NIA. The Clinical Core maintains a large pool of clinically well characterized and annually assessed research subjects for the scientific study of AD and aging, including patients with AD, other dementias, and mild cognitive impairment (MCI);normal controls, most of whom are enrolled in a brain donation program, and a growing number of Latino and Native American research subjects. This Core ensures the comparability and the productive and appropriate use of subjects, DNA, blood samples, and data from its six clinical sites. It also promotes the productive and appropriate scientific use of subjects from its independently supported APOE, Brain and Body Donation, and Clinical Therapeutics Registry Programs. The Data Management and Statistics Core maintains the ADCC's database, helps ensure the quality of data and the protection of subject confidentiality, and provides statistical services and image-analysis resources in a manner that best serves the needs of the statewide ADCC. It works closely with researchers, NACC, and other AD Centers, sharing data in the most productive, timely, and appropriate way. The Neuropathology Core provides neuropathological diagnoses and extremely high-quality brain and body tissues from expired Clinical Core and ancillary program subjects to support research studies in Arizona and around the world, helping to address a critical need in the AD research community. The Education and Information Core provides training, innovative educational and outreach programs, and strategic partnerships to promote the development of AD-related researchers, address needs of professional and family caregivers, provide information about the ADCC, address unmet needs of Arizona's Native American and rapidly growing Latino communities, and assist in the Clinical Core enrollment and study of these understudied groups.

Public Health Relevance

The Arizona Alzheimer's Disease Center (ADC) is the National Institute on Aging's (NIA's) first statewide AD Center, the only one in Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on shared scientific resources and complementary strengths from different disciplines and institutions to advance the scientific understanding, unusually early detection and tracking of AD, help address the unmet needs of Native American and Latino communities, and find demonstrably effective treatments to prevent AD symptoms as soon as possible.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-13
Application #
8501197
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
2001-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$1,356,753
Indirect Cost
$242,687
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Ren, Yingxue; van Blitterswijk, Marka; Allen, Mariet et al. (2018) TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 13:35
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Shaltouki, Atossa; Hsieh, Chung-Han; Kim, Min Joo et al. (2018) Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models. Acta Neuropathol 136:607-620
Liu, Xiaonan; Chen, Kewei; Wu, Teresa et al. (2018) Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. Transl Res 194:56-67
Sekar, Shobana; Cuyugan, Lori; Adkins, Jonathan et al. (2018) Circular RNA expression and regulatory network prediction in posterior cingulate astrocytes in elderly subjects. BMC Genomics 19:340
Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10:
Ortuño-Lizarán, Isabel; Beach, Thomas G; Serrano, Geidy E et al. (2018) Phosphorylated ?-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Mov Disord 33:1315-1324
Limback-Stokin, Martin M; Krell-Roesch, Janina; Roesler, Kimberly et al. (2018) Anticholinergic Medications and Cognitive Function in Late Midlife. Alzheimer Dis Assoc Disord 32:262-264
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 794 publications